Background and methods for the lovastatin restenosis trial after percutaneous transluminal coronary angioplasty
- 1 August 1992
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 70 (3), 293-299
- https://doi.org/10.1016/0002-9149(92)90607-z
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Initial management and long-term clinical outcome of restenosis after initially successful percutaneous transluminal coronary angioplastyThe American Journal of Cardiology, 1992
- Prevention of restenosis after percutaneous transluminal coronary angioplasty: The search for a “magic bullet”American Heart Journal, 1991
- Prevention of restenosis by lovastatin after successful coronary angioplastyAmerican Heart Journal, 1991
- Lipid-lowering therapy after an atherosclerotic eventThe American Journal of Cardiology, 1990
- Importance of stenosis morphology in the estimation of restenosis risk after elective percutaneous transluminal coronary angioplastyThe American Journal of Cardiology, 1989
- Percutaneous Transluminal Coronary Angioplasty in 1985–1986 and 1977–1981New England Journal of Medicine, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Coronary angioplasty: Clinical and angiographic follow-upThe American Journal of Cardiology, 1985
- Sex differences in early and long-term results of coronary angioplasty in the NHLBI PTCA Registry.Circulation, 1985
- Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the national heart, lung, and blood instituteThe American Journal of Cardiology, 1984